Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

It has been over four decades since the development of monoclonal antibodies (mAbs)
using a hybridoma cell line was first reported. Since then more than thirty therapeutic …

Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …

Objectives According to guidelines, a nationwide non-medical switch from originator (INX,
Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients …

Biosimilars of infliximab were first approved by the European Medicine Agency in 2013, 1, 2
based on pre-clinical studies on biosimilarity and on clinical data coming from two …

Many of the best-selling 'blockbuster'biological medicinal products are, or will soon be,
facing competition from similar biological medicinal products (biosimilars) in the EU …

Anti-tumour necrosis factor (TNF) antibodies have been widely used for approximately 25
years now. The first clinical observations in patients with refractory Crohn's disease rapidly …

Objective To evaluate drug survival, effectiveness, pharmacokinetics, immunogenicity, and
safety in daily practice after transitioning treatment from original reference infliximab …

Abstract Background and Aims: Biosimilar infliximab CT-P13 offers the potential for large
drug acquisition cost savings. However, there are limited published data regarding its …

The treatment of inflammatory bowel disease (IBD)—ulcerative colitis (UC) and Crohn's
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …